Skip to main content

Advertisement

SpringerLink
Log in

Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome

  • Review
  • Published:
Techniques in Coloproctology Aims and scope Submit manuscript

Abstract

Background

Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract characterized by abdominal discomfort, pain and changes in bowel habits, often associated with psychological/psychiatric disorders. It has been suggested that the development of IBS may be related to the body’s response to stress, which is one of the main factors that can modulate motility and visceral perception through the interaction between brain and gut (brain–gut axis). The present review will examine and discuss the role of serotonin (5-hydroxytryptamine, 5-HT) receptor subtypes in the pathophysiology and therapy of IBS.

Methods

Search of the literature published in English using the PubMed database.

Results

Several lines of evidence indicate that 5-HT and its receptor subtypes are likely to have a central role in the pathophysiology of IBS. 5-HT released from enterochromaffin cells regulates sensory, motor and secretory functions of the digestive system through the interaction with different receptor subtypes. It has been suggested that pain signals originate in intrinsic primary afferent neurons and are transmitted by extrinsic primary afferent neurons. Moreover, IBS is associated with abnormal activation of central stress circuits, which results in altered perception during visceral stimulation.

Conclusions

Altered 5-HT signaling in the central nervous system and in the gut contributes to hypersensitivity in IBS. The therapeutic effects of 5-HT agonists/antagonists in IBS are likely to be due also to the ability to modulate visceral nociception in the central stress circuits. Further studies are needed in order to develop an optimal treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA (2006) Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology 130:34–43

    CAS  PubMed  Google Scholar 

  2. Stasi C, Rosselli M, Bellini M et al (2012) Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol 47:1177–1185

    CAS  PubMed  Google Scholar 

  3. Ford AC, Talley NJ, Schoenfeld PS et al (2009) Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 58:367–378

    CAS  PubMed  Google Scholar 

  4. Bearcroft CP, Perret D, Farthing MJ (1998) Postprandial plasma 5-hydroxytryptamine in diarrhea-predominant irritable bowel syndrome: a pilot study. Gut 42:42–46

    CAS  PubMed Central  PubMed  Google Scholar 

  5. Houghton LA, Foster JM, Whorwell PJ (2003) Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 14:775–782

    Google Scholar 

  6. Spiller RC, Jenkins D, Thornley JP (2000) Increased rectal mucosal entero-endocrine cells, T lynphocytes, and increased gut permeability following acute Campilobacter enteris and in post-dysenteric irritable bowel syndrome. Gut 47:804–811

    CAS  PubMed Central  PubMed  Google Scholar 

  7. Dunlop SP, Coleman NS, Blackshaw E et al (2005) Abnormalities of 5-Hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 3:349–357

    CAS  PubMed  Google Scholar 

  8. Kim DY, Camilleri M (2000) Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 95:2698–2709

    CAS  PubMed  Google Scholar 

  9. Grundy D, Al-Chaer ED, Aziz Q et al (2006) Fundamentals of neurogastroenterology: basic science. Gastroenterology 130:1391–1411

    CAS  PubMed  Google Scholar 

  10. Varnas K, Halldin C, Hall H (2004) Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 22:246–260

    PubMed  Google Scholar 

  11. Kirchgessner AL, Liu MT, Raymond JR et al (1996) Identification of cells that express 5-hydroxytryptamine1A receptors in the nervous systems of the bowel and pancreas. J Comp Neurol 364:439–455

    CAS  PubMed  Google Scholar 

  12. Fiorica-Howells E, Hen R, Gingrich J et al (2002) 5-HT(2A) receptors: location and functional analysis in intestines of wild-type and 5-HT(2A) knockout mice. Am J Physiol Gastrointest Liver Physiol 282:G877–G893

    CAS  PubMed  Google Scholar 

  13. Hoffman JM, Tyler K, MacEachern SJ et al (2012) Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 142:844–854

    CAS  PubMed Central  PubMed  Google Scholar 

  14. Mawe GM, Branchek TA, Gershon MD (1986) Peripheral neural serotonin receptors: identification and characterization with specific antagonists and agonists. Proc Natl Acad Sci USA 83:9799–9803

    CAS  PubMed Central  PubMed  Google Scholar 

  15. Gershon MD (1999) Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 13:15–30

    PubMed  Google Scholar 

  16. Tonini M (2005) 5-Hydroxytryptamine effects in the gut: the 3, 4 and 7 receptors. Neurogastroenterol Motil 17:637–642

    CAS  PubMed  Google Scholar 

  17. Pazos A, Prost TA, Palacios JM (1987) Serotonin receptors in the human brain III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience 21:97–122

    CAS  PubMed  Google Scholar 

  18. Pineyro G, Blier P (1999) Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 51:533–591

    CAS  PubMed  Google Scholar 

  19. Wang GD, Wang XY, Zou F et al (2013) Mast cell expression of the serotonin1A receptor in guinea pig and human intestine. Am J Physiol Gastrointest Liver Physiol 304:G855–G863

    CAS  PubMed Central  PubMed  Google Scholar 

  20. Humprey PP, Hartig P, Hoyer D (1993) A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 14:233–236

    Google Scholar 

  21. Tepper SJ, Rapoport AM, Sheftell FD (2002) Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 59:1084–1088

    PubMed  Google Scholar 

  22. Hamel E, Fan E, Linville D et al (1993) Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 44:242–246

    CAS  PubMed  Google Scholar 

  23. Levy FO, Gudermann T, Peres-Reyes E et al (1992) Molecular cloning of a human serotonin receptor (S12) with a pharmacological profile resembling that of the 5-HT1D subtype. J Biol Chem 267:7553–7562

    CAS  PubMed  Google Scholar 

  24. Jin H, Oksenberg D, Ashkenazi A et al (1992) Characterization of the human 5-hydroxytryptamine1B receptor. J Biol Chem 267:5735–5738

    CAS  PubMed  Google Scholar 

  25. Weinshank RL, Zgombick JM, Macchi MJ et al (1992) Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1Dα and 5-HT1Dβ. Proc Natl Acad Sci USA 89:3630–3634

    CAS  PubMed Central  PubMed  Google Scholar 

  26. Lowther S, De Paermentier F, Crompton MR et al (1992) The distribution of 5-HT(1D) and 5-HT(lE) binding sites in human brain. Eur J Pharmacol 222:137–142

    CAS  PubMed  Google Scholar 

  27. McAllister G, Charlesworth A, Snodin C et al (1992) Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. Proc Natl Acad Sci USA 89:5517–5521

    CAS  PubMed Central  PubMed  Google Scholar 

  28. Adham N, Kao HT, Schecter LE et al (1993) Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA 90:408–412

    CAS  PubMed Central  PubMed  Google Scholar 

  29. Molderings GJ, Werner K, Likungu J et al (1990) Inhibition of noradrenaline release from the sympathetic nerves of the human saphenous vein via presynaptic 5-HT receptor similar to the 5-HT(1D) subtype. Naunyn Schmiedebergs Arch Pharmacol 342:371–377

    CAS  PubMed  Google Scholar 

  30. Bax WA, Renzenbrink GJ, Van Heuven-Nolsen D et al (1993) 5-HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol 239:203–210

    CAS  PubMed  Google Scholar 

  31. Tack J, Coulier B, Wilmer A et al (1998) Actions of the 5-hydroxytryptamine 1 receptor agonist sumatriptan on interdigestive gastrointestinal motility in man. Gut 42:36–41

    CAS  PubMed Central  PubMed  Google Scholar 

  32. Foguet M, Hoyer D, Pardo LA et al (1992) Cloning and functional characterization of the rat stomach fundus serotonin receptor. EMBO J 11:3481–3487

    CAS  PubMed Central  PubMed  Google Scholar 

  33. Bubar MJ, Cunningham KA (2006) Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem 6:1971–1985

    CAS  PubMed  Google Scholar 

  34. Vane JR (1959) The relative activities of some tryptamine analogues on the isolated rat stomach strip preparation. Br J Pharmacol 14:87–98

    CAS  Google Scholar 

  35. Cohen ML, Wittenauer LA (1987) Serotonin receptor activation of phos-phoinositide turnover in uterine, fundal, vascular and tracheal smooth muscle. J Cardiovasc Pharmacol 10:176–181

    CAS  PubMed  Google Scholar 

  36. Kursar JD, Nelson DL, Wainscott DB et al (1992) Molecular cloning, functional expression and pharmacological characterisation of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus. Mol Pharmacol 42:549–557

    CAS  PubMed  Google Scholar 

  37. Kennet GA, Aiswworth K, Trail B et al (1997) BW 723C86, a 5HT2B receptor antagonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology 36:23–39

    Google Scholar 

  38. Gershon MD (2003) Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 3:S25–S34

    PubMed  Google Scholar 

  39. Pasqualetti M, Ori M, Castagna M et al (1999) Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 92:601–611

    CAS  PubMed  Google Scholar 

  40. Boess FG, Martin IL (1994) Molecular biology of 5HT receptors. Neuropharmacology 33:275–317

    CAS  PubMed  Google Scholar 

  41. Pratt GD, Bowery NG, Kilpatrick GJ et al (1990) Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain. Trends Pharmacol Sci 11:135–137

    CAS  PubMed  Google Scholar 

  42. Thompson AJ, Lummis SC (2007) The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets 11:527–540

    CAS  PubMed Central  PubMed  Google Scholar 

  43. Kidd EJ, Laporte AM, Langlois X et al (1993) 5-HT3 receptors in the rat central nervous system are mainly located on nerve fibres and terminals. Brain Res 612:289–298

    CAS  PubMed  Google Scholar 

  44. Hamon M, Gallissot MC, Menard F et al (1989) 5-HT3 receptor binding sites are on capsaicin-sensitive fibres in the rat spinal cord. Eur J Pharmacol 164:315–322

    CAS  PubMed  Google Scholar 

  45. Takaki M (2003) Gut pacemaker cells: the interstitial cells of Cajal. J Smooth Muscle Res 39:137–161

    PubMed  Google Scholar 

  46. Liu HN, Ohya S, Nishizawa Y et al (2011) Serotonin augments gut pacemaker activity via 5-HT3 receptors. PLoS ONE 6:e24928

    CAS  PubMed Central  PubMed  Google Scholar 

  47. Marchetti E, Dumuis A, Bockaert J et al (2000) Differential modulation of the 5-HT(4) receptor agonists and antagonist on rat learning and memory. Neuropharmacology 39:2017–2027

    CAS  PubMed  Google Scholar 

  48. King MV, Marsden CA, Fone KC (2008) A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol Sci 29:482–492

    CAS  PubMed  Google Scholar 

  49. Salmon E (2007) A review of the literature on neuroimaging of serotoninergic function in Alzheimer’s disease and related disorders. J Neural Transm 114:1179–1185

    CAS  PubMed  Google Scholar 

  50. Bockaert J, Claeysen S, Compan V et al (2011) 5-HT(4) receptors, a place in the sun: act two. Curr Opin Pharmacol 11:87–93

    CAS  PubMed  Google Scholar 

  51. Madsen K, Haahr MT, Marner L et al (2011) Age and sex effects on 5-HT(4) receptors in the human brain: a [(11)C]SB207145 PET study. J Cereb Blood Flow Metab 31:1475–1481

    PubMed Central  PubMed  Google Scholar 

  52. Tack J, Camilleri M, Chang L et al (2012) Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 35:745–767

    CAS  PubMed Central  PubMed  Google Scholar 

  53. Schoemaker RG, Du XY, Bax WA et al (1993) 5-Hydroxytryptamine stimulates human isolated atrium but not ventricle. Eur J Pharmacol 239:103–105

    Google Scholar 

  54. Oliver KR, Kinsey AM, Wainwright A et al (2000) Localization of 5-HT5A receptor-like immunoreactivity in the rat brain. Brain Res 867:131–142

    CAS  PubMed  Google Scholar 

  55. Pasqualetti M, Ori M, Nardi I et al (1998) Distribution of the 5-HT5A serotonin receptor mRNA in the human brain. Mol Brain Res 56:1–8

    CAS  PubMed  Google Scholar 

  56. Plassat J-L, Boschert U, Amlaiky N et al (1992) The mouse 5-HT5A receptor reveals a remarkable heterogeneity within the 5-HT1D receptor family. EMBO J 11:4779–4786

    CAS  PubMed Central  PubMed  Google Scholar 

  57. Grailhe R, Grabtree GW, Hen R (2001) Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. Eur J Pharmacol 418:157–167

    CAS  PubMed  Google Scholar 

  58. Wesolowski A (2002) In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors. Pol J Pharmacol 54:327–341

    Google Scholar 

  59. Thomas DR, Hagan JJ (2004) 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord 3:81–90

    CAS  PubMed  Google Scholar 

  60. Tonini M, Vicini R, Cervio E et al (2005) 5-HT(7) receptors modulate peristalsis and accommodation in the guinea pig ileum. Gastroenterology 129:1557–1566

    CAS  PubMed  Google Scholar 

  61. Bülbring E, Lin RC (1985) The effect of intraluminal application of 5-hydroxytryptamine and 5-hydroxytryptophan on peristalsis; the local production of 5-HT and its release in relation to intraluminal pressure and propulsive activity. J Physiol 140:381–407

    Google Scholar 

  62. Grider JR (1994) CGRP as a transmitter in the sensory pathway mediating peristaltic reflex. Am J Physiol 266:G1139–G1145

    CAS  PubMed  Google Scholar 

  63. Danzebrink RM, Gebhart GF (1991) Evidence that spinal 5-HT1, 5-HT2 and 5-HT3 receptor subtypes modulate responses to noxious colorectal distension in the rat. Brain Res 538:64–75

    CAS  PubMed  Google Scholar 

  64. Miftahof R, Akhmadeev NR (2007) Neurochemical bases of visceral nociception: mathematical model. J Theor Biol 249:343–360

    CAS  PubMed  Google Scholar 

  65. Almeida TF, Roizenblatt S, Tufik S (2004) Afferent pain pathways: a neuroanatomical review. Brain Res 1000:40–56

    CAS  PubMed  Google Scholar 

  66. Camilleri M, Coulie B, Tack JF (2001) Visceral hypersensitivity: facts, speculations, and challenges. Gut 48:125–131

    CAS  PubMed Central  PubMed  Google Scholar 

  67. Bueno L, Fioramonti J, Delvaux M et al (1997) Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 112:1714–1743

    CAS  PubMed  Google Scholar 

  68. Keszthelyi D, Troost FJ, Jonkers DM et al (2013) Decreased levels of kynurenic acid in the intestinal mucosa of IBS patients: relation to serotonin and psychological state. J Psychosom Res 74:501–504

    PubMed  Google Scholar 

  69. Stasi C, Bellini M, Costa F et al (2013) Neuroendocrine markers and psychological features in patients with irritable bowel syndrome. Int J Colorectal Dis 28:1203–1208

    PubMed  Google Scholar 

  70. Muller-Lissner SA, Bollani S, Brummer RJ et al (2001) Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion 64:200–204

    CAS  PubMed  Google Scholar 

  71. Nakai A, Kumakura Y, Boivin M et al (2003) Sex differences of brain serotonin synthesis in patients with irritable bowel syndrome using alpha-[11C]methyl-L-tryptophan, positron emission tomography and statistical parametric mapping. Can J Gastroenterol 17:191–196

    PubMed  Google Scholar 

  72. Creed F, Fernandes L, Guthrie E et al (2003) The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 124:303–317

    PubMed  Google Scholar 

  73. Creed F, Tomenson B, Guthrie E et al (2008) The relationship between somatisation and outcome in patients with severe irritable bowel syndrome. J Psychosom Res 64:613–620

    PubMed  Google Scholar 

  74. Mayer EA, Naliboff BD, Chang L (2001) Basic pathophysiologic mechanisms in irritable bowel syndrome. Dig Dis 19:212–218

    CAS  PubMed  Google Scholar 

  75. Mertz H (2002) Role of the brain and sensory pathways in gastrointestinal sensory disorders in humans. Gastroenterology 51:i29–i33

    Google Scholar 

  76. Whitehead WE, Engel BT, Schuster MM (1980) Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. Dig Dis Sci 25:404–413

    CAS  PubMed  Google Scholar 

  77. Prior A, Maxton DG, Whorwell PJ (1990) Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects. Gut 31:458–462

    CAS  PubMed Central  PubMed  Google Scholar 

  78. Simrén M, Abrahamsson H, Bjornsson ES (2001) An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 48:20–27

    PubMed Central  PubMed  Google Scholar 

  79. Slater BJ, Plusa SM, Smith AN, Varma JS (1997) Rectal hypersensitivity in the irritable bowel syndrome. Int J Colorectal Dis 12:29–32

    CAS  PubMed  Google Scholar 

  80. Harraf F, Schmulson M, Saba L et al (1998) Subtypes of constipation predominant irritable bowel syndrome based on rectal perception. Gut 43:388–394

    CAS  PubMed Central  PubMed  Google Scholar 

  81. Steens J, Van Der Schaar PJ, Penning C et al (2002) Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Neurogastroenterol Motil 14:241–247

    CAS  PubMed  Google Scholar 

  82. Drossman DA, Ringel Y, Vogt BA et al (2003) Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology 124:754–761

    PubMed  Google Scholar 

  83. Baciu MV, Bonaz BL, Papillon E et al (1999) Central processing of rectal pain: a functional MR imaging study. Am J Neuroradiol 20:1920–1924

    CAS  PubMed  Google Scholar 

  84. Bonaz B, Baciu M, Papillon E et al (2002) Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study. Am J Gastroenterol 97:654–661

    CAS  PubMed  Google Scholar 

  85. Suzuki R, Rygh LJ, Dickenson AH (2004) Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 25:613–617

    CAS  PubMed  Google Scholar 

  86. Sharma HS, Cervos-Navarro J, Dey PK (1991) Increased blood–brain barrier permeability following acute short-term swimming exercise in conscious normotensive young rats. Neurosci Res 10:211–221

    CAS  PubMed  Google Scholar 

  87. Oatway MA, Chen Y, Weaver LC (2004) The 5-HT3 receptor facilitates at-level mechanical allodynia following spinal cord injury. Pain 110:259–268

    CAS  PubMed  Google Scholar 

  88. Borman RA, Tilford NS, Harmen DW et al (2002) 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br J Pharmacol 135:1141–1151

    Google Scholar 

  89. Beattie DT, Smith JA, Marquess D et al (2004) The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol 143:549–560

    CAS  PubMed Central  PubMed  Google Scholar 

  90. Gore S, Gilmore IT, Haigh CG et al (1990) Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 4:139–144

    CAS  PubMed  Google Scholar 

  91. Steadman CJ, Talley NJ, Phillips SF et al (1992) Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 67:732–738

    CAS  PubMed  Google Scholar 

  92. Goldberg PA, Kamm MA, Setti-Carraro P et al (1996) Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 57:478–483

    CAS  PubMed  Google Scholar 

  93. Viramontes BE, Camilleri M, McKinzie S et al (2001) Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 96:2671–2676

    CAS  PubMed  Google Scholar 

  94. Bharucha AE, Camilleri M, Haydock S et al (2000) Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. Gut 47:667–674

    CAS  PubMed Central  PubMed  Google Scholar 

  95. De Ponti F, Tonini M (2001) Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 61:317–332

    PubMed  Google Scholar 

  96. Camilleri M (2001) Review article: tegaserod. Aliment Pharmacol Ther 15:277–289

    CAS  PubMed  Google Scholar 

  97. Frampton JE (2009) Prucalopride. Drugs 69:2463–2476

    CAS  PubMed  Google Scholar 

  98. Kozlowski CM, Green A, Grundy D et al (2000) The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 46:474–480

    CAS  PubMed Central  PubMed  Google Scholar 

  99. Lee KJ, Kim NY, Kwon JK et al (2011) Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 23:1098–1104

    CAS  PubMed  Google Scholar 

  100. Schikowski A, Thewissen M, Mathis C et al (2002) Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 14:221–227

    CAS  PubMed  Google Scholar 

  101. Evans BW, Clark WK, Moore DJ et al (2007) Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 4:003960

    Google Scholar 

  102. Camilleri M, Vazquez-Roque MI, Burton D et al (2007) Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 19:30–38

    CAS  PubMed  Google Scholar 

  103. Johnson DE, Drummond E, Grimwood S et al (2012) The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations. J Pharmacol Exp Ther 341:681–691

    CAS  PubMed  Google Scholar 

  104. Manini ML, Camilleri M, Goldberg M et al (2010) Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 22(42–49):e7–e8

    Google Scholar 

  105. Hoffman JM, Tyler K, MacEachern SJ et al (2012) Activation of colonic mucosal 5-HT4 receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 142(844–854):e4

    PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Experimental and Clinical Medicine, University of Florence, Viale G.B. Morgagni, 85, 50134, Florence, Italy

    C. Stasi

  2. Health Agency of Tuscany, Florence, Italy

    C. Stasi

  3. Gastroenterology Unit, Department of Gastroenterology, University of Pisa, Pisa, Italy

    M. Bellini

  4. Gastroenterology and Hepatology Section, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy

    G. Bassotti

  5. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

    C. Blandizzi

  6. Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy

    S. Milani

Authors
  1. C. Stasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Bellini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Bassotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Blandizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Milani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Stasi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stasi, C., Bellini, M., Bassotti, G. et al. Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech Coloproctol 18, 613–621 (2014). https://doi.org/10.1007/s10151-013-1106-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10151-013-1106-8

Keywords

Search

Navigation